凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
莱茵生物(002166)公告正文

莱茵生物:2012年第三季度报告全文

公告日期 2012-10-27
股票简称:莱茵生物 股票代码:002166
                                                             桂林莱茵生物科技股份有限公司 2012 年第三季度报告全文
                                          2012 年第三季度报告一、重要提示
    本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性负个别及连带责任。
    所有董事均已出席了审议本次季报的董事会会议。
    公司负责人姚新德、主管会计工作负责人周庆伟及会计机构负责人(会计主管人员) 张为鹏声明:保证季度报告中财务报告的真实、完整。二、公司基本情况(一)主要会计数据及财务指标以前报告期财务报表是否发生了追溯调整□ 是 √ 否 □ 不适用
                                                                                         本报告期末比上年度期末增减
                                     2012.9.30                      2011.12.31
                                                                                                     (%)
    总资产(元)                               850,082,614.24               926,121,569.54                          -8.21%归属于上市公司股东的所有
                                           194,562,757.20               229,240,891.08                         -15.13%者权益(元)
    股本(股)                                 129,533,760.00               129,533,760.00                           0.00%归属于上市公司股东的每股
                                                      1.50                        1.77                         -15.25%净资产(元/股)
                               2012 年 7-9 月       比上年同期增减(%)      2012 年 1-9 月        比上年同期增减(%)
    营业总收入(元)                    71,989,852.20                 187.85%        177,600,895.25                154.39%归属于上市公司股东的净利
                                   -16,990,747.48                 -98.36%        -34,792,447.33                -11.53%润(元)经营活动产生的现金流量净
                                     --                      --                  -74,401,109.11               -396.68%额(元)每股经营活动产生的现金流
                                     --                      --                            -0.57              -378.65%量净额(元/股)
    基本每股收益(元/股)                       -0.13                 -85.71%                  -0.27               -12.50%
    稀释每股收益(元/股)                       -0.13                 -85.71%                  -0.27               -12.50%
    加权平均净资产收益率(%)                  -8.34%                  -4.07%                -16.42%                -1.65%扣除非经常性损益后的加权
                                           -8.44%                  -4.14%                -17.50%                -1.53%平均净资产收益率(%)扣除非经常性损益项目和金额√ 适用 □ 不适用
                                                       年初至报告期期末金
                        项目                                                                       说明
                                                           额(元)非流动资产处置损益越权审批或无正式批准文件的税收返还、减免
                                                              桂林莱茵生物科技股份有限公司 2012 年第三季度报告全文计入当期损益的政府补助(与企业业务密切相关,按照
                                                                 1,496,447.66国家统一标准定额或定量享受的政府补助除外)
    计入当期损益的对非金融企业收取的资金占用费                        525,166.68企业取得子公司、联营企业及合营企业的投资成本小于取得投资时应享有被投资单位可辨认净资产公允价值产生的收益非货币性资产交换损益委托他人投资或管理资产的损益因不可抗力因素,如遭受自然灾害而计提的各项资产减值准备债务重组损益企业重组费用,如安置职工的支出、整合费用等交易价格显失公允的交易产生的超过公允价值部分的损益同一控制下企业合并产生的子公司期初至合并日的当期净损益与公司正常经营业务无关的或有事项产生的损益除同公司正常经营业务相关的有效套期保值业务外,持有交易性金融资产、交易性金融负债产生的公允价值变动损益,以及处置交易性金融资产、交易性金融负债和可供出售金融资产取得的投资收益单独进行减值测试的应收款项减值准备转回对外委托贷款取得的损益采用公允价值模式进行后续计量的投资性房地产公允价值变动产生的损益根据税收、会计等法律、法规的要求对当期损益进行一次性调整对当期损益的影响受托经营取得的托管费收入
    除上述各项之外的其他营业外收入和支出                              789,793.23其他符合非经常性损益定义的损益项目少数股东权益影响额
    所得税影响额                                                      -511,130.67
    合计                                                             2,300,276.90                    --公司对“其他符合非经常性损益定义的损益项目”以及根据自身正常经营业务的性质和特点将非经常性损益项目界定为经常性损益的项目的说明
          项目                   涉及金额(元)                                   说明(二)报告期末股东总数及前十名股东持股情况表
    报告期末股东总数(户)                                                                                          39,684
                                        前十名无限售条件流通股股东持股情况
                                期末持有无限售条件股份的                        股份种类及数量
         股东名称
                                          数量                          种类                          数量
                       秦本军                     14,383,504 人民币普通股                                    14,383,504
                                                          桂林莱茵生物科技股份有限公司 2012 年第三季度报告全文
                    蒋安明                     4,331,576 人民币普通股                               4,331,576
                    姚新德                     3,400,402 人民币普通股                               3,400,402
                    黎科弟                      302,500 人民币普通股                                  302,500
                    经伟庆                      277,600 人民币普通股                                  277,600国泰君安证券股份有限公司客
                                                236,010 人民币普通股                                  236,010
    户信用交易担保证券账户
                    王龙花                      216,000 人民币普通股                                  216,000
                      刘蕊                      165,000 人民币普通股                                  165,000
                    陈巧云                      161,479 人民币普通股                                  161,479
                    李国华                      156,880 人民币普通股                                  156,880
                             公司股东秦本军先生与蒋安明先生为兄弟关系,属于一致行动人,除上述关联关系以外,公股东情况的说明
                             司前 3 大股东之间不存在关联关系或一致行动,其他股东之间关系不详。三、重要事项(一)公司主要会计报表项目、财务指标大幅度变动的情况及原因√ 适用 □ 不适用
    1、报告期末公司资产负债表项目大幅度变动及原因:
         项目            本报告期末         年初数      增减金额(±) 增减(±%)
    货币资金                 20,766,780.33    74,764,663.71 -53,997,883.38        -72.22%
    应收账款                 81,705,039.38    53,348,168.95 28,356,870.43          53.15%
    预付款项                 26,223,964.54    67,598,397.81 -41,374,433.27        -61.21%
    应付账款                139,602,739.45 219,533,351.50 -79,930,612.05          -36.41%
    应交税费                 -3,384,815.23      -729,993.42 -2,654,821.81        -363.68%
    长期借款                140,000,000.00    30,000,000.00 110,000,000.00        366.67%
    未分配利润              -26,979,641.64     7,812,805.69 -34,792,447.33       -445.33%
    货币资金较期初减少72.22%,主要系报告期购买原料支出增加及支付竞拍所得土地款所致;
    应收帐款较期初增加53.15%,主要系报告期销售增长,未到账期的货款增加所致;
    预付款项较期初减少61.21%,主要系报告期收到临桂新区管委会退回BT项目建设保证金所致;
    应付账款较期初减少36.41%,主要系报告期支付竞拍所得土地款所致;
    应交税费较期初减少363.68%,主要系报告期缴纳上年度税款所致;
    长期借款较期初增加366.67%,主要系报告期银行长期贷款增加所致;
    未分配利润较期初减少445.33%,主要系报告期出现亏损所致。
    2、报告期公司利润表项目大幅度变动及原因:
          项目             2012年1-9月        上年同期     增减金额(±) 增减(±%)
    营业收入                    177,600,895.25 69,815,698.10 107,785,197.15       154.39%
    营业成本                    157,963,231.70 54,518,778.75 103,444,452.95       189.74%
    财务费用                     24,427,303.37 18,788,701.66       5,638,601.71    30.01%
    投资收益                        161,994.00 2,501,917.81      -2,339,923.81    -93.53%
    所得税费用                     -524,080.39      494,424.68   -1,018,505.07   -206.00%
    营业收入同比上年增加154.39%,主要系报告期公司植物提取业务大幅增长以及新增BT项目收入所致;
    营业成本同比上年增加189.74%,主要系报告期营业收入增加而营业成本相应增加所致;
    财务费用同比上年增加30.01%,主要系报告期银行贷款相比上年同期增加所致;
    投资收益同比上年减少93.53%,主要系报告期尚未收到部分公司所投资企业的分红所致;
                                                  桂林莱茵生物科技股份有限公司 2012 年第三季度报告全文
    所得税费用同比上年减少206%,主要系报告期冲减上年度多计所得税所致;
    3、报告期公司现金流量表项目大幅度变动及原因:
              项目                2012年1-9月      上年同期        增减金额(±)      增减(±%)
    经营活动产生的现金流量净额       -74,401,109.11   -14,979,791.59    -59,421,317.52          -396.68%
    投资活动产生的现金流量净额            633,155.60 -208,417,111.25    209,050,266.85           100.30%
    筹资活动产生的现金流量净额        19,717,130.45   130,782,748.79 -111,065,618.34             -84.92%
    经营活动产生的现金流量净额同比减少396.68%,主要系报告期购买原料支出增加及支付竞拍所得土地款所致;
    投资活动产生的现金流量净额同比增加100.30%,主要系上年同期支付BT项目综合费用所致;
    筹资活动产生的现金流量净额同比减少84.92%,主要系报告期偿还银行贷款及其他暂借款所致。(二)重大事项进展情况及其影响和解决方案的分析说明1、非标意见情况□ 适用 √ 不适用2、公司存在向控股股东或其关联方提供资金、违反规定程序对外提供担保的情况□ 适用 √ 不适用3、日常经营重大合同的签署和履行情况√ 适用 □ 不适用
    2011年8月30日,公司披露了《关于全资子公司桂林莱茵投资有限公司签订BT项目合同的公告》。莱茵投资与湖南省建筑工程集团总公司、湖南省建工园林工程有限公司组成的联合体与桂林市临桂新区管理委员会、桂林市临桂新区城市建设投资有限公司、桂林市大禹水利基础设施建设投资有限公司签订了《桂林市临桂新区防洪排涝及湖塘水系工程投资、建设与移交合同书》,该项目总投资估算约人民币16.2亿元。截至本报告期末,大皇山闸坝工程、中心环形水域防洪排涝及湖塘水系工程共2个单位工程开工建设,大皇山闸坝工程已基本完工,中心环形水域防洪排涝及湖塘水系工程已完成工程总量的22%左右。公司根据《企业会计准则第15号-建造合同》的规定,确认2012年1-9月BT项目合同收入2,814万元。
    2011年11月1日,公司披露了《关于竞得土地使用权的公告》。公司全资孙公司桂林锦汇投资有限公司成功竞得临桂县国土资源局2011-39号、2011-40号两宗地块的土地使用权,成交总金额为人民币2.76亿元。目前,锦汇投资尚在开展前述地块利用开发的前期工作。
    2011年11月4日,公司披露了《关于签订日常经营重大合同的公告》。公司及全资子公司LAYN USA与美国嘉吉股份有限公司营养健康事业部正式签订了一份关于甜菊糖最终产品的长期独家《外包加工及供应协议》。截至本报告期末,公司累计收到美国嘉吉公司订单1850万美元,2012年1-9月执行订单金额为924万美元。4、其他√ 适用 □ 不适用
    2011 年 5 月 12 日,公司披露了《关于签订信托贷款合同的公告》,经公司第二届董事会第二十五次会议审议通过,2011 年度第 1 次临时股东大会审议批准,公司与江西国际信托股份有限公司签订了信托贷款合同,贷款金额 2 亿元,期限 12 个月。2012 年 3 月 28 日,公司与江西国际信托股份有限公司签订补充协议,将前述 2 亿元贷款展期 1 年。
    2011 年 12 月 30 日,公司披露了《关于签订收储协议的公告》。公司与兴安县土地储备中心签订了《公
                                                              桂林莱茵生物科技股份有限公司 2012 年第三季度报告全文司兴安县湘江路厂区国有土地使用权收储协议》,兴安县土地储备中心以 9,852.05 万元作为补偿费用对公司兴安厂区土地及其附属资产(设备除外)进行收储。截至本报告期末,公司已完成进行设备、树木等收储范围之外资产的搬迁工作。(三)公司或持股 5%以上股东在报告期内或持续到报告期内的承诺事项√ 适用 □ 不适用
               承诺事项                  承诺人              承诺内容         承诺时间       承诺期限    履行情况股改承诺收购报告书或权益变动报告书中所作承诺资产置换时所作承诺
                                                    不在中国境内外直
                                                    接或间接从事或参
                                                    与任何在商业上对
                                                    公司构成竞争的业
                                                    务或活动,或拥有与
                                                    公司存在竞争关系
                                     公司发起人股 的任何经济实体、机
    发行时所作承诺                       东秦本军、姚新 构、经济组织的权 2007 年 09 月 13 日 长期            正在履行
                                     德及蒋安明     益,或以其他任何形
                                                    式取得该经济实体、
                                                    机构、经济组织的控
                                                    制权,或在该经济实
                                                    体、机构、经济组织
                                                    中担任高级管理人
                                                    员或核心技术人员。其他对公司中小股东所作承诺
    承诺是否及时履行                     √ 是 □ 否 □ 不适用
    未完成履行的具体原因及下一步计划     不适用是否就导致的同业竞争和关联交易问题
                                   □ 是 □ 否 √ 不适用作出承诺
    承诺的解决期限                       长期
    解决方式                             长期履行
    承诺的履行情况                       正在履行(四)对 2012 年度经营业绩的预计2012 年度预计的经营业绩情况:业绩亏损业绩亏损
    2012 年度净利润亏损(万元)                                  0                  至                500
    2011 年度归属于上市公司股东的净利润(元)                                                               2,526,157.20
                                            2012 年 4 季度,公司植物提取业务销售有望继续增长,同时,公司全资子
    业绩变动的原因说明                          公司承接的 BT 项目实施符合预期,预计将会对公司年度业绩产生较大影
                                            响。
                                                           桂林莱茵生物科技股份有限公司 2012 年第三季度报告全文(五)其他需说明的重大事项1、证券投资情况□ 适用 √ 不适用2、衍生品投资情况□ 适用 √ 不适用3、报告期末衍生品投资的持仓情况□ 适用 √ 不适用4、报告期内接待调研、沟通、采访等活动登记表
                                                                                               谈论的主要内容及
    接待时间              接待地点       接待方式         接待对象类型         接待对象
                                                                                                   提供的资料5、发行公司债券情况是否发行公司债券□ 是 √ 否四、附录(一)财务报表是否需要合并报表:√ 是 □ 否 □ 不适用如无特殊说明,财务报告中的财务报表的单位为:人民币元1、合并资产负债表编制单位: 桂林莱茵生物科技股份有限公司
                                                                                                          单位: 元
                    项目                             期末余额                              期初余额流动资产:
    货币资金                                                   20,766,780.33                         74,764,663.71
    结算备付金
    拆出资金
    交易性金融资产
    应收票据
    应收账款                                                   81,705,039.38                         53,348,168.95
    预付款项                                                   26,223,964.54                         67,598,397.81
    应收保费
                             桂林莱茵生物科技股份有限公司 2012 年第三季度报告全文
    应收分保账款
    应收分保合同准备金
    应收利息                     7,221,027.79                        6,695,861.11
    应收股利
    其他应收款                  60,023,767.98                       59,027,629.42
    买入返售金融资产
    存货                       451,865,456.62                      447,356,571.39
    一年内到期的非流动资产
    其他流动资产                  403,532.59
    流动资产合计                   648,209,569.23                      708,791,292.39非流动资产:
    发放委托贷款及垫款
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                26,030,000.00                       26,030,000.00
    投资性房地产
    固定资产                   148,604,499.85                      164,786,670.39
    在建工程                      100,000.00
    工程物资
    固定资产清理                 1,076,830.83
    生产性生物资产
    油气资产
    无形资产                    24,555,155.43                       25,007,047.86
    开发支出
    商誉
    长期待摊费用
    递延所得税资产               1,506,558.90                        1,506,558.90
    其他非流动资产
    非流动资产合计                 201,873,045.01                      217,330,277.15
    资产总计                       850,082,614.24                      926,121,569.54流动负债:
    短期借款                   332,471,266.70                      334,700,000.00
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    交易性金融负债
    应付票据                                                        28,000,000.00
    应付账款                   139,602,739.45                      219,533,351.50
    预收款项                     1,043,847.15                         841,585.77
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                  632,485.51                         1,146,398.08
                                                        桂林莱茵生物科技股份有限公司 2012 年第三季度报告全文
    应交税费                                                 -3,384,815.23                         -729,993.42
    应付利息                                                  1,496,313.16                         807,736.42
    应付股利
    其他应付款                                               11,345,878.80                       51,521,580.86
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    一年内到期的非流动负债                                   20,626,566.00                       21,253,132.00
    其他流动负债
    流动负债合计                                                503,834,281.54                      657,073,791.21非流动负债:
    长期借款                                                140,000,000.00                       30,000,000.00
    应付债券
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债                                           11,480,534.00                        9,572,534.00
    非流动负债合计                                              151,480,534.00                       39,572,534.00
    负债合计                                                    655,314,815.54                      696,646,325.21所有者权益(或股东权益):
    实收资本(或股本)                                      129,533,760.00                      129,533,760.00
    资本公积                                                 83,217,530.86                       83,217,530.86
    减:库存股
    专项储备
    盈余公积                                                  8,834,943.24                        8,834,943.24
    一般风险准备
    未分配利润                                              -26,979,641.64                        7,812,805.69
    外币报表折算差额                                            -43,835.26                         -158,148.71
    归属于母公司所有者权益合计                                  194,562,757.20                      229,240,891.08
    少数股东权益                                               205,041.50                          234,353.25
    所有者权益(或股东权益)合计                                194,767,798.70                      229,475,244.33
    负债和所有者权益(或股东权益)总计                          850,082,614.24                      926,121,569.54
    法定代表人:姚新德                    主管会计工作负责人:周庆伟                    会计机构负责人:张为鹏2、母公司资产负债表编制单位: 桂林莱茵生物科技股份有限公司
                                                                                                     单位: 元
                 项目                            期末余额                            期初余额流动资产:
    货币资金                                                 12,376,531.68                       60,736,523.55
                             桂林莱茵生物科技股份有限公司 2012 年第三季度报告全文
    交易性金融资产
    应收票据
    应收账款                    66,159,587.44                       57,981,918.93
    预付款项                     4,489,937.65                        2,764,333.71
    应收利息
    应收股利
    其他应收款                  56,871,829.84                       51,194,635.33
    存货                       142,066,710.64                      155,229,954.82
    一年内到期的非流动资产
    其他流动资产
    流动资产合计                   281,964,597.25                      327,907,366.34非流动资产:
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资               503,184,924.59                      500,184,924.59
    投资性房地产
    固定资产                     6,159,883.22                       14,325,082.56
    在建工程
    工程物资
    固定资产清理                  -562,556.38
    生产性生物资产
    油气资产
    无形资产                      714,988.29                          743,715.13
    开发支出
    商誉
    长期待摊费用
    递延所得税资产               2,278,239.89                        2,278,239.89
    其他非流动资产
    非流动资产合计                 511,775,479.61                      517,531,962.17
    资产总计                       793,740,076.86                      845,439,328.51流动负债:
    短期借款                   332,471,266.70                      324,700,000.00
    交易性金融负债
    应付票据
    应付账款                    63,153,679.19                       27,986,062.82
    预收款项                     1,043,847.15                         841,585.77
    应付职工薪酬                   524,411.82                         880,923.98
    应交税费                      787,321.16                         3,115,425.54
    应付利息                      276,757.60                          690,494.75
    应付股利
    其他应付款                  36,970,210.95                      218,429,390.13
    一年内到期的非流动负债        301,566.00                          603,132.00
                                                        桂林莱茵生物科技股份有限公司 2012 年第三季度报告全文
    其他流动负债
    流动负债合计                                                435,529,060.57                      577,247,014.99非流动负债:
    长期借款                                                110,000,000.00
    应付债券
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债                                            5,118,034.00                        4,697,534.00
    非流动负债合计                                              115,118,034.00                        4,697,534.00
    负债合计                                                    550,647,094.57                      581,944,548.99所有者权益(或股东权益):
    实收资本(或股本)                                      129,533,760.00                      129,533,760.00
    资本公积                                                 85,883,914.34                       85,883,914.34
    减:库存股
    专项储备
    盈余公积                                                  8,834,943.24                        8,834,943.24
    一般风险准备
    未分配利润                                               18,840,364.71                       39,242,161.94
    外币报表折算差额
    所有者权益(或股东权益)合计                                243,092,982.29                      263,494,779.52
    负债和所有者权益(或股东权益)总计                          793,740,076.86                      845,439,328.51
    法定代表人:姚新德                    主管会计工作负责人:周庆伟                    会计机构负责人:张为鹏3、合并本报告期利润表编制单位: 桂林莱茵生物科技股份有限公司
                                                                                                     单位: 元
                 项目                            本期金额                            上期金额
    一、营业总收入                                               71,989,852.20                       25,009,470.77
    其中:营业收入                                           71,989,852.20                       25,009,470.77
           利息收入
           已赚保费
           手续费及佣金收入
    二、营业总成本                                               89,854,188.66                       35,001,962.83
    其中:营业成本                                           67,737,910.26                       19,552,836.82
           利息支出
           手续费及佣金支出
           退保金
           赔付支出净额
           提取保险合同准备金净额
           保单红利支出
                                                                桂林莱茵生物科技股份有限公司 2012 年第三季度报告全文
             分保费用
             营业税金及附加                                           617,940.19                             1,646.74
             销售费用                                               2,710,203.16                         2,242,027.84
             管理费用                                               7,656,732.94                         8,620,057.84
             财务费用                                              11,131,402.11                         4,585,393.59
             资产减值损失
      加    :公允价值变动收益(损失以“-”号填列)
             投资收益(损失以“-”号填
                                                                                                         2,501,917.81列)
          其中:对联营企业和合营企业的投资收益
             汇兑收益(损失以“-”号填列)                            143,314.70                          -607,885.73
    三、营业利润(亏损以“-”号填列)                                 -17,721,021.76                       -8,098,459.98
       加   :营业外收入                                              371,540.76                           57,567.73
       减   :营业外支出                                              194,000.00                           32,863.00
             其中:非流动资产处置损失
    四、利润总额(亏损总额以“-”号填列)                             -17,543,481.00                       -8,073,755.25
       减:所得税费用                                                -546,035.27                          494,424.68
    五、净利润(净亏损以“-”号填列)                                 -16,997,445.73                       -8,568,179.93
       其中:被合并方在合并前实现的净利润
       归属于母公司所有者的净利润                                  -16,990,747.48                       -8,565,672.22
       少数股东损益                                                     -6,698.25                           -2,507.71
    六、每股收益:                                             --                                   --
       (一)基本每股收益                                                   -0.13                               -0.07
       (二)稀释每股收益                                                   -0.13                               -0.07
    七、其他综合收益                                                       19,103.59                           -18,008.58
    八、综合收益总额                                                   -16,978,342.14                       -8,586,188.51
       归属于母公司所有者的综合收益总
                                                                   -16,971,643.89                       -8,583,680.80额
       归属于少数股东的综合收益总额                                     -6,698.25                           -2,507.71本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元。
    法定代表人:姚新德                           主管会计工作负责人:周庆伟                     会计机构负责人:张为鹏4、母公司本报告期利润表编制单位: 桂林莱茵生物科技股份有限公司
                                                                                                            单位: 元
                   项目                                 本期金额                             上期金额
    一、营业收入                                                       69,552,013.70                        24,287,599.28
       减:营业成本                                                63,463,783.51                        18,722,717.93
            营业税金及附加                                            249,251.67
            销售费用                                                1,632,864.56                         1,709,369.62
                                                            桂林莱茵生物科技股份有限公司 2012 年第三季度报告全文
        管理费用                                                 4,585,826.24                         4,914,598.95
        财务费用                                                 7,968,165.66                         9,025,516.38
        资产减值损失
    加:公允价值变动收益(损失以“-”号填列)
        投资收益(损失以“-”号填列)                                                                2,501,917.81
        其中:对联营企业和合营企业的投资收益
    二、营业利润(亏损以“-”号填列)                              -8,347,877.94                        -7,582,685.79
    加:营业外收入                                                184,974.66                             70,000.00
    减:营业外支出                                                  80,000.00                            32,863.00
        其中:非流动资产处置损失
    三、利润总额(亏损总额以“-”号填列)                          -8,242,903.28                        -7,545,548.79
    减:所得税费用
    四、净利润(净亏损以“-”号填列)                              -8,242,903.28                        -7,545,548.79
    五、每股收益:                                         --                                   --
    (一)基本每股收益                                                  -0.06                                -0.06
    (二)稀释每股收益                                                  -0.06                                -0.06六、其他综合收益
    七、综合收益总额                                                -8,242,903.28                        -7,545,548.79
    法定代表人:姚新德                       主管会计工作负责人:周庆伟                     会计机构负责人:张为鹏5、合并年初到报告期末利润表编制单位: 桂林莱茵生物科技股份有限公司
                                                                                                         单位: 元
                 项目                               本期金额                             上期金额
    一、营业总收入                                                 177,600,895.25                        69,815,698.10
    其中:营业收入                                             177,600,895.25                        69,815,698.10
          利息收入
          已赚保费
          手续费及佣金收入
    二、营业总成本                                                 215,304,683.69                       104,428,375.61
    其中:营业成本                                             157,963,231.70                        54,518,778.75
          利息支出
          手续费及佣金支出
          退保金
          赔付支出净额
          提取保险合同准备金净额
          保单红利支出
          分保费用
          营业税金及附加                                         1,836,237.19                             5,198.43
          销售费用                                               7,660,699.45                         7,089,884.18
                                                                桂林莱茵生物科技股份有限公司 2012 年第三季度报告全文
             管理费用                                               22,603,920.76                       23,765,752.13
             财务费用                                               24,337,017.45                       17,515,541.53
             资产减值损失                                             903,577.14                         1,533,220.59
      加    :公允价值变动收益(损失以“-”号填列)
             投资收益(损失以“-”号填
                                                                      161,994.00                         2,501,917.81列)
          其中:对联营企业和合营企业的投资收益
             汇兑收益(损失以“-”号填列)                             -90,285.92                        -1,273,160.13
    三、营业利润(亏损以“-”号填列)                                 -37,632,080.36                       -33,383,919.83
       加   :营业外收入                                             2,685,604.63                        2,714,078.74
       减   :营业外支出                                              399,363.74                            38,600.35
             其中:非流动资产处置损失
    四、利润总额(亏损总额以“-”号填列)                             -35,345,839.47                       -30,708,441.44
       减:所得税费用                                                 -524,080.39                          494,424.68
    五、净利润(净亏损以“-”号填列)                                 -34,821,759.08                       -31,202,866.12
       其中:被合并方在合并前实现的净
                                                                             0.00                                0.00利润
       归属于母公司所有者的净利润                                  -34,792,447.33                       -31,196,376.52
       少数股东损益                                                    -29,311.75                            -6,489.60
    六、每股收益:                                             --                                   --
       (一)基本每股收益                                                   -0.27                                -0.24
       (二)稀释每股收益                                                   -0.27                                -0.24
    七、其他综合收益                                                       -43,835.26                           -40,018.59
    八、综合收益总额                                                   -34,865,594.34                       -31,242,884.71
       归属于母公司所有者的综合收益总
                                                                   -34,836,282.59                       -31,236,395.11额
       归属于少数股东的综合收益总额                                    -29,311.75                            -6,489.60年初到报告期末发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元。
    法定代表人:姚新德                           主管会计工作负责人:周庆伟                     会计机构负责人:张为鹏6、母公司年初到报告期末利润表编制单位: 桂林莱茵生物科技股份有限公司
                                                                                                            单位: 元
                   项目                                 本期金额                             上期金额
    一、营业收入                                                       144,968,502.60                       72,479,325.90
       减:营业成本                                                128,534,721.05                       57,088,668.12
            营业税金及附加                                            767,506.83
            销售费用                                                 5,106,486.70                        5,265,750.42
            管理费用                                                13,557,188.34                       13,521,527.51
            财务费用                                                18,881,576.62                       20,947,470.46
            资产减值损失                                              537,481.78                         1,490,085.18
                                                            桂林莱茵生物科技股份有限公司 2012 年第三季度报告全文
    加:公允价值变动收益(损失以“-”号填列)
        投资收益(损失以“-”号填列)                            161,994.00                         2,501,917.81
        其中:对联营企业和合营企业的投资收益
    二、营业利润(亏损以“-”号填列)                             -22,254,464.72                       -23,332,257.98
    加:营业外收入                                               1,602,704.92                        2,081,488.12
    减:营业外支出                                                284,163.74                            38,600.35
        其中:非流动资产处置损失
    三、利润总额(亏损总额以“-”号填列)                         -20,935,923.54                       -21,289,370.21
    减:所得税费用                                                -534,126.31
    四、净利润(净亏损以“-”号填列)                             -20,401,797.23                       -21,289,370.21
    五、每股收益:                                         --                                   --
    (一)基本每股收益                                                  -0.16                                -0.16
    (二)稀释每股收益                                                  -0.16                                -0.16六、其他综合收益
    七、综合收益总额                                               -20,401,797.23                       -21,289,370.21
    法定代表人:姚新德                       主管会计工作负责人:周庆伟                     会计机构负责人:张为鹏7、合并年初到报告期末现金流量表编制单位: 桂林莱茵生物科技股份有限公司
                                                                                                        单位: 元
                 项目                               本期金额                             上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                               150,237,137.02                       79,419,339.86
    客户存款和同业存放款项净增加额
    向中央银行借款净增加额
    向其他金融机构拆入资金净增加额
    收到原保险合同保费取得的现金
    收到再保险业务现金净额
    保户储金及投资款净增加额
    处置交易性金融资产净增加额
    收取利息、手续费及佣金的现金
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还                                               3,058,818.44                        6,054,596.12
    收到其他与经营活动有关的现金                                54,043,976.48                        5,375,652.79
    经营活动现金流入小计                                           207,339,931.94                       90,849,588.77
    购买商品、接受劳务支付的现金                               226,597,718.53                       65,595,581.06
    客户贷款及垫款净增加额
    存放中央银行和同业款项净增加额
    支付原保险合同赔付款项的现金
                                        桂林莱茵生物科技股份有限公司 2012 年第三季度报告全文
       支付利息、手续费及佣金的现金
       支付保单红利的现金
       支付给职工以及为职工支付的现金      15,537,967.84                       13,692,263.18
       支付的各项税费                       6,196,728.87                        1,500,907.32
       支付其他与经营活动有关的现金        33,408,625.81                       25,040,628.80
    经营活动现金流出小计                      281,741,041.05                      105,829,380.36
    经营活动产生的现金流量净额                -74,401,109.11                      -14,979,791.59二、投资活动产生的现金流量:
       收回投资收到的现金
       取得投资收益所收到的现金              161,994.00                         2,501,917.81
    处置固定资产、无形资产和其他长
                                            5,867,170.00期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
       收到其他与投资活动有关的现金
    投资活动现金流入小计                        6,029,164.00                        2,501,917.81
    购建固定资产、无形资产和其他长
                                            5,396,008.40                       10,919,029.06期资产支付的现金
       投资支付的现金
       质押贷款净增加额
    取得子公司及其他营业单位支付的现金净额
       支付其他与投资活动有关的现金                                           200,000,000.00
    投资活动现金流出小计                        5,396,008.40                      210,919,029.06
    投资活动产生的现金流量净额                   633,155.60                      -208,417,111.25三、筹资活动产生的现金流量:
       吸收投资收到的现金
    其中:子公司吸收少数股东投资收到的现金
       取得借款收到的现金                 283,242,496.37                      275,000,000.00
       发行债券收到的现金
       收到其他与筹资活动有关的现金        84,000,000.00                       36,200,000.00
    筹资活动现金流入小计                      367,242,496.37                      311,200,000.00
       偿还债务支付的现金                 175,550,762.80                       62,000,000.00
       分配股利、利润或偿付利息支付的
                                           22,841,982.48                       12,789,326.21现金
    其中:子公司支付给少数股东的股利、利润
       支付其他与筹资活动有关的现金       149,132,620.64                      105,627,925.00
    筹资活动现金流出小计                      347,525,365.92                      180,417,251.21
    筹资活动产生的现金流量净额                 19,717,130.45                      130,782,748.79四、汇率变动对现金及现金等价物的影
                                               52,939.68                         -145,383.59响
    五、现金及现金等价物净增加额              -53,997,883.38                      -92,759,537.64
       加:期初现金及现金等价物余额        74,764,663.71                      100,027,962.67
                                                        桂林莱茵生物科技股份有限公司 2012 年第三季度报告全文
    六、期末现金及现金等价物余额                                 20,766,780.33                         7,268,425.03
    法定代表人:姚新德                    主管会计工作负责人:周庆伟                    会计机构负责人:张为鹏8、母公司年初到报告期末现金流量表编制单位: 桂林莱茵生物科技股份有限公司
                                                                                                     单位: 元
               项目                              本期金额                            上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                            136,184,408.45                       75,769,582.69
    收到的税费返还                                            3,058,818.44                         6,054,596.12
    收到其他与经营活动有关的现金                              2,623,615.84                       43,482,184.13
    经营活动现金流入小计                                        141,866,842.73                      125,306,362.94
    购买商品、接受劳务支付的现金                            163,384,279.90                       75,698,187.16
    支付给职工以及为职工支付的现金                            7,591,200.18                         7,646,995.20
    支付的各项税费                                            4,884,498.57                          468,066.71
    支付其他与经营活动有关的现金                             16,543,879.80                       16,083,684.22
    经营活动现金流出小计                                        192,403,858.45                       99,896,933.29
    经营活动产生的现金流量净额                                  -50,537,015.72                       25,409,429.65二、投资活动产生的现金流量:
    收回投资收到的现金
    取得投资收益所收到的现金                                   161,994.00                          2,501,917.81
    处置固定资产、无形资产和其他长
                                                              5,867,170.00期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
    投资活动现金流入小计                                          6,029,164.00                         2,501,917.81
    购建固定资产、无形资产和其他长
                                                               486,329.00                           163,023.40期资产支付的现金
    投资支付的现金                                            3,000,000.00                      202,754,924.59
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
    投资活动现金流出小计                                          3,486,329.00                      202,917,947.99
    投资活动产生的现金流量净额                                    2,542,835.00                      -200,416,030.18三、筹资活动产生的现金流量:
    吸收投资收到的现金
    取得借款收到的现金                                      243,242,496.37                      235,000,000.00
    发行债券收到的现金
    收到其他与筹资活动有关的现金                             48,000,000.00                       26,200,000.00
    筹资活动现金流入小计                                        291,242,496.37                      261,200,000.00
    偿还债务支付的现金                                      125,550,762.80                       62,000,000.00
    分配股利、利润或偿付利息支付的                           18,976,957.48                         9,955,404.54
                                                        桂林莱茵生物科技股份有限公司 2012 年第三季度报告全文现金
       支付其他与筹资活动有关的现金                       147,132,620.64                      106,607,925.00
    筹资活动现金流出小计                                      291,660,340.92                      178,563,329.54
    筹资活动产生的现金流量净额                                   -417,844.55                       82,636,670.46四、汇率变动对现金及现金等价物的影
                                                               52,033.40                          -84,657.31响
    五、现金及现金等价物净增加额                              -48,359,991.87                      -92,454,587.38
       加:期初现金及现金等价物余额                        60,736,523.55                       97,532,456.19
    六、期末现金及现金等价物余额                               12,376,531.68                        5,077,868.81
    法定代表人:姚新德                    主管会计工作负责人:周庆伟                    会计机构负责人:张为鹏(二)审计报告公司第三季度财务报告未经会计师事务所审计。
                                                                               董事长:姚新德
                                                                   董事会批准报送日期:2012 年 10 月 25 日
数据加载中...
prevnext
手机查看股票